INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTV
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Artiva Biotherapeutics, Inc. ("Artiva" or the "Company") (NASDAQ: ARTV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
Covered in this story
Analyst targets on Artiva Biotherapeutics
- Jefferies: at $4.23 · target $4 by Oct 2027 · Hold via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ARTV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Artiva Biotherapeutics →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.